Function and application of A20 combined nuclear factor profilin 1(ABIN1) in cardiac hypertrophy treatment

A technology to inhibit protein and cardiac hypertrophy, applied in the field of gene function and application, to achieve the effect of protecting heart function

Inactive Publication Date: 2015-12-09
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, no reports have found the role of ABIN-1 in cardiovascular diseases, especially myocardial diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Function and application of A20 combined nuclear factor profilin 1(ABIN1) in cardiac hypertrophy treatment
  • Function and application of A20 combined nuclear factor profilin 1(ABIN1) in cardiac hypertrophy treatment
  • Function and application of A20 combined nuclear factor profilin 1(ABIN1) in cardiac hypertrophy treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] The establishment of embodiment 1 mouse myocardial hypertrophy model

[0060] Aortic arch constriction (AB) was used to establish a mouse model of myocardial hypertrophy, and the operation procedure of the model was as follows:

[0061] 1.1 Animal selection

[0062] Wild-type mice (WT), ABIN1 knockout mice (ABIN1-KO), cardiac-specific ABIN1 transgenic mice (ABIN1-TG) and non-transgenic mice aged 8-10 weeks and weighing 23.5-27.5 g were selected. Mice (NTG) were divided into sham operation group (sham) and AB myocardial hypertrophy model group, that is, WTsham group, WTAB group, ABIN1-KOsham group, ABIN1-KOAB group, ABIN1-TGsham group, ABIN1-TGAB group, NTGsham group, NTGAB group, 10 mice in each group.

[0063] 1.2 Preoperative preparation

[0064] (1) Anesthesia: First weigh the mice, calculate the required amount of anesthetic (3% pentobarbital sodium) according to 90 mg / kg body weight, inject intraperitoneally, and record the injection time point. There is no obv...

Embodiment 2

[0072] Example 2 Detection of cardiac hypertrophy and fibrosis in myocardial hypertrophy model mice

[0073] 1. Take materials

[0074] (1) Preliminary work: prepare in advance a urine cup filled with 20mL of 10% formaldehyde by volume, and label it (mouse number, group, type of operation and date of collection). Place a petri dish filled with 10% KCl solution in mass fraction at the sampling site. Turn on the analytical balance and set it to zero for later use. Mice were then weighed and sacrificed.

[0075] (2) Material collection: Ophthalmic curved forceps clamped the vascular pedicle below the atrial appendage, cut off the heart, and quickly placed it in a 10% KCl solution. After the heart stops beating in the diastolic phase, place it on sterilized gauze, gently squeeze the fluid in the heart cavity, dip the surface fluid dry, weigh and record, put the heart into the corresponding urine cup, fix it for 48 hours and use it for pathological testing.

[0076] (3) Releva...

Embodiment 3

[0091] Example 3 Cardiac Function Detection of Myocardial Hypertrophy Model Mice

[0092] Ultrasound testing of heart function

[0093] 1. Preliminary preparation

[0094] (1) Anesthesia machine preparation: first connect the oxygen cylinder and the air inlet port on the anesthesia machine, then unscrew the sealing cap of the dosing port on the anesthesia machine, quickly add isoflurane to the safety scale, and then tighten the sealing cap. Unscrew the main valve on the oxygen cylinder, adjust the knob of the flow control valve, and maintain the outlet pressure at 0.2-0.3mPa.

[0095] (2) Preparation of the mice to be tested: After the mice to be tested were quickly anesthetized with isoflurane, the hair on the left chest area was shaved, and the head of the treated mice was inserted into the anesthetic catheter sleeve, and treated with 1.5-2.0% isoflurane Alkane maintains a stable state of anesthesia in mice.

[0096] 2. Cardiac function test

[0097] The mice were placed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a function and application of A20 combined nuclear factor profilin 1(ABIN1) in cardiac hypertrophy treatment and belongs to the field of gene functions and application. The relation between the expression of ABIN1 and cardiac hypertrophy is determined, and a research result shows that the cardiac hypertrophy and fibrosis are remarkably promoted by inhibiting the RGS14 expression, and heart functions are worsened; the cardiac hypertrophy and fibrosis are remarkably inhibited by promoting RGS14 overexpression, and the heart functions are protected. Thus, ABIN1 can serve as a target gene, is used for screening medicine capable of protecting the heart, resisting cardiac fibrosis and / or preventing, relieving and / or treating cardiac hypertrophy, is used for preparing the medicine capable of protecting the heart, resisting cardiac hypertrophy and / or preventing, relieving and / or treating cardiac hypertrophy, and provides an effective new means for treatment of cardiac hypertrophy.

Description

technical field [0001] The invention belongs to the field of gene function and application, and particularly relates to the function and application of A20-binding nuclear factor inhibitory protein 1 (A20-Binding Inhibitors of NF-κB1, ABIN-1) in the treatment of myocardial hypertrophy. Background technique [0002] Myocardial hypertrophy is an adaptive compensatory response of myocardial cells to the stimulation of neurohumoral factors and changes in mechanical stress load. It is a complex and dynamic process that incorporates many factors involved in regulation. Cardiomyopathy, cardiomyopathy and other common pathological processes that need to be experienced in the development of most cardiovascular diseases[1]. Myocardial hypertrophy is an adaptive compensatory response of the heart to various cardiovascular stimuli such as hemodynamic load, angiotensin, growth factors, and hormones, which can reduce the pressure on the ventricular wall and maintain or even increase cardi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61K48/00A61K45/00A61P9/04G01N33/68
Inventor 李红良王丕晓张晓晶姬燕晓梅芳华
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap